Russell LaMontagne
Founder at Boston Immune Technologies & Therapeutics, Inc.
Network origin in Russell LaMontagne first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Boston Immune Technologies & Therapeutics, Inc.
 Boston Immune Technologies & Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Immune Technologies & Therapeutics, Inc. is a company based in MA that develops a novel class of antagonist antibodies targeting the TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease. The company is based in Winchester, MA. The company is also developing additional TNF superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology. The company was founded by Russell LaMontagne and he has been the CEO since incorporation.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Russell LaMontagne via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| University of Wisconsin | College/University | Doctorate Degree | |
| The University of Chicago | College/University | Undergraduate Degree | |
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
GRO Biosciences, Inc.
 GRO Biosciences, Inc. Pharmaceuticals: MajorHealth Technology GRO Biosciences, Inc. develops genomically recoded organisms to express therapeutic proteins. The company was founded by George McDonald Church, Andrew D. Ellington, Daniel J. Mandell, Christopher J. Gregg, P. Benjamin Stranges, Marc J. Lajoie, and Ross Thyer in 2016 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Qiming US Ventures Management, LLC
 Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Analyst | |
Enveda Therapeutics, Inc.
 Enveda Therapeutics, Inc. BiotechnologyHealth Technology Enveda Therapeutics, Inc. is a biotechnology company based in Boulder, CO. The company has developed a drug discovery search engine that utilizes metabolomics and machine learning to create a high-resolution chemical map of the natural world. Enveda's team includes experienced drug hunters and data scientists who work together to tackle the toughest problems in drug discovery. The company was founded by Viswa Colluru and Pieter Dorrestein, with Viswa Colluru serving as CEO since incorporation. | Biotechnology | Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 10 |
Sectoral
| Health Technology | 5 |
| Finance | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 5 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
| Corporate Officer/Principal | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Bruce A. Beutel | 10 |
| Denise Faustman | 1 |
- Stock Market
- Insiders
- Russell LaMontagne
- Company connections
